Skip to main content

Table 7 Owner assessment of pruritus using a visual analogue scale (PVAS) for dogs naturally infested with fleas and administered either fluralaner or afoxolaner treatments

From: Evaluation of fluralaner and afoxolaner treatments to control flea populations, reduce pruritus and minimize dermatologic lesions in naturally infested dogs in private residences in west central Florida USA

Treatment group   Days post-Treatmenta
  Day 0 Day 28–30 Day 54–60 Day 82–86
Fluralaner b # Dogs 34 34 33 33
Mean PVAS Scored 7.3 1.7 0.9 0.9
STDEV 2.40 1.8 1.2 1.3
Range (2.2–10) (0-6) (0-4.2) (0-4.2)
Reductione   77.0 % 87.5 % 88.0 %
Afoxolaner c # Dogs 27 27 26 23
Mean PVAS Scored 7.1 1.5 0.7 0.7
STDEV 2.2 1.8 0.9 1.4
Range (2.7–10) (0-6.5) (0-3.6) (0-6.7)
Reduction   79.2 % 89.6 % 89.7 %
  1. aIn both groups dogs were treated on day 0. In the afoxolaner group dogs were also treated once between days 28–30 and once between days 54–60
  2. bDogs were orally administered fluralaner chews (Bravecto® Merck Animal Health) according to label directions
  3. cDogs were orally administered afoxolaner chewables (NexGard® Merial, Inc.) according to label directions
  4. dArithmetic mean pruritus score as assessed by dog owners using the PVAS (Hill et al. Vet Dermatol 18(5):301–308, 2004)
  5. e{(Day 0 arithmetic mean FAD score—day x arithmetic mean FAD score)/day 0 arithmetic mean FAD score)} x 100